G. B. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
G. B. Jones has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
F. S. Fouad
1 shared publication
Latest Publications
- 1 December 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (27) , 2415-2440
Designed Enediyne Antitumor Agents
Abstract: The enediynes remain among the most potent antitumoral agents to have been discovered in the past decade. Following prodrug activation, the enediynes undergo cycloaromatization reactions resulting in formation of highly reactive diradical intermediates. The diradical species engage in atom-transfer chemistry to produce neutral arene products, in the process inducing damage to key macromolecules. Several of the naturally occurring members of the enediyne family of antibiotics have entered clinical trials, and this has prompted the design of synthetic enediynes, where the enediyne ‘warhead’ is conjugated to a targeted delivery vehicle. This review will describe ecent efforts using chemical synthesis to identify and improve the target specificity of designed enediynes, and to establish efficient methods to achieve prodrug activation. Finally, new horizons will be examined, including the use of post-cycloaromatized enediyne templates as recognition elements for unique DNA and RNA microenvironments.
- 1 December 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (27) , 2415-2440
Designed Enediyne Antitumor Agents
Abstract: The enediynes remain among the most potent antitumoral agents to have been discovered in the past decade. Following prodrug activation, the enediynes undergo cycloaromatization reactions resulting in formation of highly reactive diradical intermediates. The diradical species engage in atom-transfer chemistry to produce neutral arene products, in the process inducing damage to key macromolecules. Several of the naturally occurring members of the enediyne family of antibiotics have entered clinical trials, and this has prompted the design of synthetic enediynes, where the enediyne ‘warhead’ is conjugated to a targeted delivery vehicle. This review will describe ecent efforts using chemical synthesis to identify and improve the target specificity of designed enediynes, and to establish efficient methods to achieve prodrug activation. Finally, new horizons will be examined, including the use of post-cycloaromatized enediyne templates as recognition elements for unique DNA and RNA microenvironments.